Moderna, Inc. (BMV:MRNA)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.06T +495.2% |
| Revenue (ttm) | 38.93B -27.6% |
| Net Income | -55.06B |
| EPS | -139.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96 |
| Open | 2,700.00 |
| Previous Close | 2,688.50 |
| Day's Range | 2,610.00 - 2,740.00 |
| 52-Week Range | 414.00 - 2,975.59 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna stock rises 8%: can it continue its cancer vaccine success rally?
Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company's personalised mRNA cancer vaccine and a series of analyst upgrades and higher pric...
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Moderna Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Positive phase III melanoma data validates the T-cell priming approach, with broad ongoing trials in lung, bladder, and renal cancers. Manufacturing is already at commercial scale, supporting global trials and future launches. The expanding vaccine portfolio and innovative mRNA technology underpin growth and margin confidence.
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Moderna cancer vaccine BREAKTHROUGH drives new hope after phase 3 trial
Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent me...
Beyond NVDA: New Frontiers in Space Stocks, Healthcare AI
Sydney Armani, CEO of AI Fintech World Group, discusses Nvidia (NVDA) continuing its climb after a stellar earnings report, with 2028 revenue projections soaring and its dominance in data center code ...
Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets
Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
Moderna Stock (MRNA) Drops as Rothschild Downgrades to ‘Sell’ on Valuation Concerns
Moderna ($MRNA) stock was down about 3% in Thursday’s pre-market trading after Rothschild Redburn analyst Simon Baker downgraded his rating on the biotechnology stock to Sell from Hold on valuation…
Moderna downgraded to Sell from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn downgraded Moderna (MRNA) to Sell from Neutral with a price target of $81, up from $40. The firm views the Phase 3 INTerpath-001 trial of intismeran…
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Moderna to Present at Upcoming Conferences in September 2026
CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global H...
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna has also purchased a hedge overl...
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Stephane Bancel, CEO of Moderna , was at a Lebanese restaurant celebrating a friend's birthday late on August 13 when he got the call.
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applica...
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna will also purchase a hedge overl...
Was Moderna Stock's 440% Surge Hiding In Plain Sight?
This article was written by Doug Nathman, with research by his team at Trefis.
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotechnology
Moderna's 177% stock surge followed its mRNA cancer vaccine success, but CEO Stéphane Bancel says China's biotechnology investments pose a threat.